CRA was retained in an international arbitration between two Japanese affiliates of multinational pharmaceutical companies. The dispute concerned Respondent’s performance under a co-promotion agreement. CRA assessed indicators of commercially reasonable efforts using various industry data sources. CRA also quantified Claimant’s loss resulting from the alleged inadequate performance under the agreement, and responded to Respondent’s expert regarding damages alleged by Respondent.
Regulatory changes present new sources of renewable energy disputes
Despite the continuing effect of the pandemic on financing, investment and construction in many countries, the Americas continued to see substantial additions...